The Relative Strength (RS) Rating for Ionis Pharmaceuticals (IONS) stock moved into a new percentile Wednesday, as it got a lift from 65 to 79.
XAs you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks compares to the rest of the market.
History shows that the market's biggest winners typically have an 80 or higher RS Rating as they launch their largest price moves. See if Ionis Pharmaceuticals stock can continue to rebound and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Is Ionis Pharmaceuticals Stock A Buy?
Ionis Pharmaceuticals stock is building a cup without handle with a 48.92 entry. See if it can break out in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company showed 0% earnings growth in the latest quarterly report, while sales growth came in at -8%.
Ionis Pharmaceuticals stock holds the No. 299 rank among its peers in the Medical-Biomed/Biotech industry group. Arcturus Therapeutics (ARCT) and Vertex Pharmaceuticals (VRTX) are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MAY ALSO LIKE:
MarketSmith's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
